Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in drug therapy for multiple sclerosis.

P F Smith1, C L Darlington

  • 1Department of Pharmacology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New software dedicated to virtual mazes for human cognitive investigations.

Journal of neuroscience methods·2019
Same author

The critical role of vestibular graviception during cognitive-motor development.

Behavioural brain research·2019
Same author

Hippocampal LTP modulation and glutamatergic receptors following vestibular loss.

Brain structure & function·2018
Same author

Flow cytometry for receptor analysis from ex-vivo brain tissue in adult rat.

Journal of neuroscience methods·2018
Same author

Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.

Epidemiology and infection·2018
Same author

Further studies of the effects of aging on arginine metabolites in the rat vestibular nucleus and cerebellum.

Neuroscience·2017
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Racial identity, marginalization, and depression in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Disability and race in MS: Does socioeconomic disadvantage play a role?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Multiple sclerosis (MS) management involves symptomatic treatments like baclofen and corticosteroids for relapses. Research focuses on disease-modifying therapies, with interferons showing effectiveness and new treatments in trials.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) presents with diverse symptoms impacting patients.
  • Current management includes symptomatic relief and treatment of acute relapses.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for multiple sclerosis.
  • To highlight drugs for symptomatic management and disease modification.

Main Methods:

  • Literature review of pharmacological interventions for MS.
  • Categorization of treatments based on symptomatic relief versus disease modification.

Main Results:

  • Symptomatic treatments include antispastics, tremor reducers, anticholinergics, anti-epileptics, stimulants, and antidepressants.
  • Corticosteroids like methylprednisolone are standard for acute relapses.

Related Experiment Videos

  • Beta- and alpha-interferons are effective disease-modifying therapies; numerous other treatments are under investigation.

    • Conclusions:

    • MS treatment requires a multifaceted approach addressing symptoms and disease progression.
    • Interferons represent a key advancement in disease modification, with ongoing research exploring novel therapies.